Monday, May 27, 2024
Facebook Linkedin Twitter
HomeTagsInterim Analysis

Interim Analysis

Biotechnology

Ionis Announces Eplontersen Met Co-primary and Secondary Endpoints in Interim Analysis of the Phase 3 NEURO-TTRansform Study

PR Newswire -
Ionis Pharmaceuticals, Inc. announced positive topline results from a 35-week interim analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's eplontersen in...
Biotechnology

Eiger BioPharmaceuticals Announces Second Positive Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Patients

PR Newswire -
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics

Load more
ReadMagazine © | All rights reserved |Contact Us | Privacy Policy| Become A Guest Writer | Advertise with Us